N the past, considerable research focused on the role that cigarette smoking plays in the incidence of SAH, but very little attention was paid to the relationship between smoking and death as a result of the disease. Most studies that have been performed have been hospital based. It is well recognized that there is a significant prehospitalization mortality rate in patients with SAH and, therefore, hospital-based studies are, by definition, biased in favor of less severely affected patients. The development of a population-based database of all patients who have suffered SAH in two English counties has allowed a unique opportunity to explore the effect a history of smoking has on the risk of death in patients with SAH.
sive/hypervolemic treatment 1 was used to manage vasospasm as needed.
Case Selection
Multiple overlapping methods of case identification were used. 1) The patient administration systems of all five district general hospitals in the two counties were searched for all patients who had been assigned discharge diagnosis codes consistent with SAH (Table 1) between January 1, 1992 and December 31, 1996.
2) The Office of National Statistics provided a list of all people with Devon and Cornwall postal codes who had died during the study period and in whom the cause of death had been classified as SAH according to codes in their files, as specified earlier.
3) The imaging database at Plymouth was searched for all patients who had undergone cerebral angiography during the study period. 4) The surgical database at Plymouth was searched for all patients who had undergone aneurysm surgery during the study period (Office of Population, Census and Statistics codes: L30-L309, L33-L339).
All medical records were reviewed by the author. Records held in the offices of patients' general practitioners were obtained for people who had not been admitted to the hospital. A diagnosis of SAH was accepted if there was a history of abrupt onset of severe headache or unconsciousness accompanied by signs of meningeal irritation, with or without focal neurological signs supported by CT or autopsy evidence of SAH. In a small number of cases no CT scanning or autopsy had been performed; these cases were only included if there were no focal signs at onset, and a typical history was verified by a uniformly bloody and xanthochromic cerebrospinal fluid demonstrated by a nontraumatic lumbar puncture.
Careful elimination of all duplicate entries was performed based on surname and date of birth. To eliminate possible duplication of women who had married and changed their surnames during the study period, a check was made for any female patient who had the same first name and date of birth. People who normally resided outside Devon and Cornwall, and patients with a primary history of head trauma or a primary intracerebral hemorrhage were excluded. Patients were only included if they presented with SAH for the first time. Patients in whom angiography revealed arteriovenous malformations and those receiving warfarin or suffering from a clotting disorder were also excluded.
Information on premorbid smoking and hypertension was extracted from medical records by using a standard questionnaire. Patients were considered to have hypertension if there was documentation of two instances prior to hemorrhage when diastolic pressure was greater than 95 mm Hg or systolic pressure was greater than 160 mm Hg, or if they were taking antihypertension medication at the time their SAH occurred. Cigarette smoking was classified as either current or none, the latter category including persons who had never smoked and those who had stopped smoking 6 months or longer before onset of the SAH.
Statistical Analysis
Groups were compared using the Student t-test and the chi-square test for continuous variables and proportions, respectively. The null hypothesis was rejected when the probability value was less than 0.05. Confidence intervals for counted data were calculated by assuming a Poisson distribution. The influence of various factors on mortality at 1, 7, and 30 days post-SAH were compared by calculating RRs. Multivariate logistic regression analysis was used to examine the influence of those factors found to be related to mortality while controlling for all others. 
Results
Eight hundred twenty-four cases of first SAH were found. The diagnosis was verified by review of CT scans in 634 patients (77%), autopsy findings in 180 (22%), and a typical history and lumbar puncture in 10 patients (1%). Twenty-four patients were excluded because they harbored arteriovenous malformations. In the remaining cohort there were 516 female patients (64%) and 284 male patients. The mean age of the cohort was 61.3 years and the median was 62 years. Female patients were significantly older than males (p Ͻ 0.0005). The mean age for female patients was 63.2 years (range 11-96 years) and that for male patients was 57.7 years (range 19-91 years). Eighty-five percent of the patients were older than 45 years of age. Two hundred eighty-four patients (36%) were current smokers at the time of their SAH. There was a 10-year age difference between the mean age of smok- Of the 800 patients, 409 (51%) had survived to undergo angiography. Three hundred thirty-nine of these patients were shown to have an aneurysm (17% negative angiogram rate). Aneurysms were also found in all 181 patients who had undergone autopsy. Therefore, a total of 520 patients (65%) in the entire cohort were shown to have aneurysms.
Case Mortality Rates
One hundred twenty-nine (16%) of the 800 patients died without having received medical attention and an additional 41 patients reached the hospital, but died within 24 hours, making the case mortality rate for the day of SAH 21% (95% CI 19-25%). The case mortality rates at 1 week and 30 days post-SAH for the entire cohort were 37% (95% CI 33-44%) and 44% (95% CI 39-48%), respectively. Figure 1 presents cumulative mortality rates by smoking history for the first 30 days post-SAH. In both groups the rates rose steeply for the first 3 days and then leveled off, suggesting that the damage caused by the initial hemorrhage is responsible for the greatest proportion of the 30-day mortality rate. The case fatality rates at 1, 7, and 30 days post-SAH for smokers were 14%, 25%, and 29%, respectively, whereas those for nonsmokers were 26%, 43%, and 52%, respectively. Table 2 presents the RRs of mortality at 1, 7, and 30 days following SAH. A history of hypertension is not related to death at any time interval. Female patients were more likely to die as a result of their SAH, but the CIs do just contain the number 1. The risk of death is 43% higher in female than in male patients at 24 hours post-SAH. Patient age is strongly related to mortality and, rather perversely, smoking seems to be protective. Sixty-six percent of smokers were younger than 60 years old, a lowrisk group, and 60% of smokers were female, a high-risk group. When age, sex, and smoking status were entered into a logistic regression, age remained an important predictor of mortality at all time intervals, and smoking was found to be still protective at 7 and 30 days post-SAH.
Discussion
It is generally recognized that studies of the incidence of cerebrovascular disease should be conducted prospectively, because many stroke episodes are mild and medical attention is not always sought. 13 This reasoning is less cogent in a study of SAH, which is virtually always a dramatic event. In this study the risk of missing patients who died before reaching medical attention is minimal, because in the UK any sudden unexpected death, the hallmark of fatal SAH, is reported to the coroner and conducting an autopsy is routine.
Findings of many studies have confirmed the positive correlation between patient age and mortality, but the prognostic significance of preexisting hypertension has remained unclear. Authors of some studies have suggested that patients with hypertension fare worse than other patients, 7, 15 whereas other authors have been unable to confirm this. 5, 12 The findings in the present study indicate fairly clearly that preexisting hypertension has no effect on mortality.
The most surprising finding in this study is the protective effect of current smoking against death following SAH. This should be accepted with caution, in view of the retrospective nature of this study. It is possible that a systematic bias could be operating, with inaccurate smoking status more common in those who died within 30 days. This may be a particular problem in those patients who died outside the hospital or who presented unconscious. In view of the universally recognized impact of cigarette smoking on health, however, a person's smoking history is an essential part of the medical record. For those patients who entered the hospital, the admission procedure included a checklist that requires notation of smoking status. General practitioner records contain similar checklists, and it was believed that in only eight cases was smoking history indeterminate.
It has been recognized for some time that there is increased incidence of SAH in smokers, and numerous articles have been published that document smoking prevalence in these patients. If there was a misclassification of smoking status in the present cohort, it is more likely that smokers would have received codes assigned to nonsmokers, rather than the reverse. This should lead to an overall underestimate of smoking prevalence. A comparison of rates of smoking from previous studies with those noted in the present study may be instructive. Prospective population-based studies are rare, but the authors of two such studies from Finland (midyear of one study 1969 10 and midyear of the other study 1977 6 ) reported smoking rates in patients younger than 70 years of age to be 51% (95% CI 41-62%) and 48% (95% CI 36-62%), respectively. In the present study the rate of smoking in patients younger than 70 years of age was 47% (95% CI 41-53%). In view of the general decline in smoking over the last two decades, the rate in the present study appears high. The best available source for a comparison is probably the European arm of the prospective hospital-based tirilazad trial (midyear of study 1993). 19 The rate of smoking calculated from the large database that the study encompassed was 46% (95% CI 43-49%), which is in close agreement with the smoking rate of hospitalized patients in the present cohort (45%). The highest rates of smoking were reported in a hospital-based study in London, UK (midyear of study 1971), 2 in which investigators found that the smoking rate in patients with proven aneurysms was 77% (95% CI 66-90%). In the present study, conducted 25 years later, the rate of smoking in patients with aneurysms was significantly lower, that is, 53% (95% CI 45-61%). In another hospital-based study in the UK, the authors reported smoking rates in Merseyside (midyear of study 1990) 14 to be 60% (95% CI 50-71%). The rates in the London and Merseyside studies (both retrospective and subject to the same biases as the present study) seem out of step with those from the much larger prospective European tirilazad trial, 19 but overall, it is reassuring to see that smoking rates in the present cohort are not wildly out of step with those previously reported.
There is little information in the literature regarding the influence of smoking on case mortality rates for SAH. A population-based study in King County, Washington, United States of America, contains a description of the clinical course of SAH in 171 patients. 12 The authors of this work found that patients with poor outcomes at 30 days post-SAH had slightly higher mean pack-years of cigarette smoking than those with good outcomes, but the difference was not statistically significant. Smokers were not compared with nonsmokers. Unusually, only 3% of this population died before reaching medical attention, suggesting that some immediately fatal cases may have been missed. The authors of a highly selective study in Finland of 291 patients with aneurysm-proven SAH reported good outcome rates at 1 year in nonsmokers and smokers as 64% and 60%, respectively. 9 The difference was not significant. The authors of a hospital-based study undertaken in the UK reported outcomes at 6 months in 217 patients; 14 good outcome was reported in 78% of smokers and 72% of nonsmokers, but the difference was not statistically significant, perhaps because of the small numbers.
It is interesting to speculate on whether there could be a biologically plausible mechanism for a protective effect of smoking in SAH. It is clear from this study, as well as from many others, that the most powerful determinant of survival in this disease is the severity of the initial hemorrhage. 4 If smoking does have a protective effect, it would somehow have to mitigate this primary event.
There is no clear evidence regarding what determines the amount of bleeding that occurs during an SAH. It is likely that platelets play a significant role, however, and it is known that there is increased platelet aggregation in smokers. 8 This could form part of a credible explanation for smokers' improved survival.
There has also been speculation that immediate vasospasm may restrict the initial hemorrhage, and evidence from animal experiments 3 and clinical studies 17 indicate that vasospasm can immediately follow SAH. Patients who are current smokers have been shown to have an increased risk of vasospasm following SAH. 11, 19 It is generally accepted that the initial vasospasm occurs within minutes and that delayed vasospasm starts on Day 3 post-SAH, reaches a peak on Day 6 or 7, and then subsides. 18 It could be postulated that smoking is protective by virtue of its potentiation of cerebral vasospasm; if this is the case, one would expect this benefit to diminish on Day 3 post-SAH, as the second phase of vasospasm begins. To explore the time course of the protective effect of smoking, I constructed Fig. 2 , which plots the smoker/ nonsmoker RR of death at 30 days against the day post-SAH in a censored group of patients (RRs calculated only in patients alive on that day). Smokers are most protected (lowest RR) on Days 2, 8, 9, and 10 post-SAH. The RR begins to rise on Day 3 and reduces again on Day 7, mirroring the time course of delayed vasospasm. On Days 5 and 6, which is the peak of vasospasm, 95% CIs include 1, suggesting that on these days there is no protection from smoking. These data would support the theory that smoking intensifies the vasospasm immediately following SAH and, thus, limits the severity of the initial hemorrhage. Once delayed vasospasm begins, the increased risk of vasospasm in smokers negates the initial protective effect. In those patients who survive the period of maximum vasospasm (Day 8 post-SAH), the initial protective effect again becomes predominant.
Conclusions
The results of this study indicate that the risk of death from SAH in smokers is almost half that of nonsmokers. Examination of the time course of this protection indicates that vasospasm may limit the amount of hemorrhage. Further investigation into the relationship of smoking and mortality may provide insight into the mechanisms at work in the immediate aftermath of SAH.
